Skip to main content
Premium Trial:

Request an Annual Quote

KineMed, GSK Partner on Biomarker Discovery Deal

NEW YORK (GenomeWeb News) – KineMed today announced an agreement with GlaxoSmithKline for the use of KineMed's biomarker discovery platform in therapeutic areas of interest for the drug manufacturer.

The deal is aimed at the discovery, optimization, and validation of novel biomarkers for use in clinical trials directed at compounds for muscle wasting, fibrosis, and metabolic diseases. Marc Hellerstein, KineMed's chief of the scientific advisory board, said that reliable biomarkers that measure the therapeutic impact of drugs on the underlying disease processes are the missing links in developing drugs that target such diseases.

"KineMed's technology, which measures the dynamics of cellular biochemical networks, is focused on developing better metrics of the disease pathology of those disorders and therefore generates competitive advantage in developing effective drugs against them," he said in a statement.

Financial and other terms of the multiyear deal were not disclosed.

Based in Emeryville, Calif., KineMed discovers and develops biomarkers. It announced a deal with CHDI Foundation targeting Huntington's disease, and one with Pfizer to develop diabetes treatments, as GenomeWeb Daily News sister publication ProteoMonitor has reported.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more